Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$16.48 USD

16.48
1,898,347

+1.17 (7.64%)

Updated Jul 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Retain Charles River (CRL) Stock For Now

Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.

Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes

Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.

Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects

Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.

Here's Why You Should Retain Amedisys (AMED) Stock For Now

Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.

Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer

Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.

Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal

Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.

Medtronic (MDT) Reports Positive Findings Backing RDN System

Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.

Here's Why Owens & Minor (OMI) Looks Ripe for Bottom Fishing

Owens & Minor (OMI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?

Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.

Is Owens & Minor (OMI) a Great Stock for Value Investors?

Is Owens & Minor (OMI) a great pick from the value investor's perspective right now? Read on to know more.

The Zacks Analyst Blog Highlights Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co.

Owens & Minor, Thermo Fisher Scientific, Medtronic and Becton, Dickinson and Co. have been included in this Analyst Blog.

Riya Anand headshot

3 Stocks to Focus on With MedTech M&A Scaling New Heights

MedTech stocks like Owens & Minor (OMI), Thermo Fisher (TMO) and Medtronic (MDT) are prudent investment choices given their long-term growth potential with recent M&A deals.

Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales

Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.

Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm

WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.

Here's Why You Should Hold on to LabCorp (LH) Stock For Now

Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.

Allscripts (MDRX) Unveils Newly Rebranded App Expo Site

Allscripts' (MDRX) rebranded App Expo site to offer developers an opportunity to present their certified solutions online.

Here's Why You Should Retain Syneos Health (SYNH) For Now

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing

Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

Here's Why You Should Retain Chemed (CHE) Stock For Now

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.

Here's Why You Should Retain SmileDirectClub (SDC) For Now

Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.

ResMed's (RMD) SaaS Arm Strength Aids Growth, Supply Woes Stay

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.